L A Deveza1, V B Kraus2, J E Collins3, A Guermazi4, F W Roemer4,5, M C Nevitt6, D J Hunter1. 1. a Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute , University of Sydney , Sydney , NSW , Australia. 2. b Duke Molecular Physiology Institute and Division of Rheumatology , Duke University School of Medicine , Durham , NC , USA. 3. c Department of Orthopaedic Surgery Brigham and Women's Hospital , Orthopaedic and Arthritis Center for Outcomes Research , Boston , MA , USA. 4. d Quantitative Imaging Center, Department of Radiology , Boston University School of Medicine , Boston , MA , USA. 5. e Department of Radiology , University of Erlangen-Nuremberg , Erlangen , Germany. 6. f Department of Epidemiology and Biostatistics , University of California , San Francisco , CA , USA.
Abstract
OBJECTIVES: To determine the relationship between synovitis detected on non-contrast-enhanced (non-CE) magnetic resonance imaging (MRI), biochemical markers of inflammation, and clinical assessment of effusion in people with knee osteoarthritis (OA). METHOD: We examined data from the OA Biomarkers Consortium within the Osteoarthritis Initiative (n = 600). Non-CE MRIs were semi-quantitatively scored (grades 0-3) for severity of Hoffa synovitis and effusion synovitis. Serum (s) matrix metalloproteinase-3 (sMMP-3), hyaluronic acid (sHA), and nitrated epitope of the α-helical region of type II collagen (sColl2-1NO2) were quantified. The bulge and patellar tap clinical tests were performed at baseline and performance characteristics were assessed for the detection of effusion synovitis on MRI. Multinomial logistic regression adjusted for covariates was used to assess the association between biochemical and imaging markers at baseline and over 12 and 24 months. RESULTS: At baseline, sHA and sMMP-3 were associated with moderate to large (score ≥ 2, n = 117) effusion synovitis, with odds ratio = 1.35 and 1.30 per 1 standard deviation in biochemical markers (95% confidence intervals 1.07, 1.71 and 1.00, 1.69), c-statistics 0.640 and 0.626, respectively. The c-statistics for the presence of Hoffa synovitis (score ≥ 2) were 0.693, 0.694, and 0.694 for sHA, sMMP-3, and sColl2-1NO2, respectively. There was no significant association between biochemical markers (baseline and 12 and 24 month time-integrated concentrations) and changes in MRI markers. The bulge and patellar tap signs were 22.0% and 4.3% sensitive and 88.8% and 94.8% specific, respectively, for detecting effusion synovitis (score ≥ 1) on MRI. CONCLUSIONS: sHA and sMMP-3 were modestly associated with effusion synovitis at baseline. Clinical signs of effusion are insensitive but highly specific for the presence of any effusion synovitis on non-CE MRI.
OBJECTIVES: To determine the relationship between synovitis detected on non-contrast-enhanced (non-CE) magnetic resonance imaging (MRI), biochemical markers of inflammation, and clinical assessment of effusion in people with knee osteoarthritis (OA). METHOD: We examined data from the OA Biomarkers Consortium within the Osteoarthritis Initiative (n = 600). Non-CE MRIs were semi-quantitatively scored (grades 0-3) for severity of Hoffa synovitis and effusion synovitis. Serum (s) matrix metalloproteinase-3 (sMMP-3), hyaluronic acid (sHA), and nitrated epitope of the α-helical region of type II collagen (sColl2-1NO2) were quantified. The bulge and patellar tap clinical tests were performed at baseline and performance characteristics were assessed for the detection of effusion synovitis on MRI. Multinomial logistic regression adjusted for covariates was used to assess the association between biochemical and imaging markers at baseline and over 12 and 24 months. RESULTS: At baseline, sHA and sMMP-3 were associated with moderate to large (score ≥ 2, n = 117) effusion synovitis, with odds ratio = 1.35 and 1.30 per 1 standard deviation in biochemical markers (95% confidence intervals 1.07, 1.71 and 1.00, 1.69), c-statistics 0.640 and 0.626, respectively. The c-statistics for the presence of Hoffa synovitis (score ≥ 2) were 0.693, 0.694, and 0.694 for sHA, sMMP-3, and sColl2-1NO2, respectively. There was no significant association between biochemical markers (baseline and 12 and 24 month time-integrated concentrations) and changes in MRI markers. The bulge and patellar tap signs were 22.0% and 4.3% sensitive and 88.8% and 94.8% specific, respectively, for detecting effusion synovitis (score ≥ 1) on MRI. CONCLUSIONS:sHA and sMMP-3 were modestly associated with effusion synovitis at baseline. Clinical signs of effusion are insensitive but highly specific for the presence of any effusion synovitis on non-CE MRI.
Authors: Jolanda Cibere; Nicholas Bellamy; Anona Thorne; John M Esdaile; Kelly J McGorm; Andrew Chalmers; Simon Huang; Paul Peloso; Kam Shojania; Joel Singer; Hubert Wong; Jacek Kopec Journal: Arthritis Rheum Date: 2004-02
Authors: Frank W Roemer; C Kent Kwoh; Michael J Hannon; David J Hunter; Felix Eckstein; Tomoko Fujii; Robert M Boudreau; Ali Guermazi Journal: Arthritis Rheumatol Date: 2015-05 Impact factor: 10.995
Authors: Daichi Hayashi; Frank W Roemer; Avinash Katur; David T Felson; Seoung-Oh Yang; Faris Alomran; Ali Guermazi Journal: Semin Arthritis Rheum Date: 2011-02-03 Impact factor: 5.532
Authors: Mukundan Attur; Jonathan Samuels; Svetlana Krasnokutsky; Steven B Abramson Journal: Best Pract Res Clin Rheumatol Date: 2010-02 Impact factor: 4.098
Authors: W Wirth; M-P Hellio Le Graverand; B T Wyman; S Maschek; M Hudelmaier; W Hitzl; M Nevitt; F Eckstein Journal: Osteoarthritis Cartilage Date: 2008-09-11 Impact factor: 6.576
Authors: Aurang Z Khawaja; Deirdre B Cassidy; Julien Al Shakarchi; Damian G McGrogan; Nicholas G Inston; Robert G Jones Journal: Insights Imaging Date: 2015-08-08
Authors: Terence W O'Neill; Matthew J Parkes; Nasimah Maricar; Elizabeth J Marjanovic; Richard Hodgson; Andrew D Gait; Timothy F Cootes; Charles E Hutchinson; David T Felson Journal: Ann Rheum Dis Date: 2015-06-26 Impact factor: 19.103
Authors: Ana M Valdes; Srinivasarao Ravipati; Petros Pousinis; Cristina Menni; Massimo Mangino; Abhishek Abhishek; Victoria Chapman; David A Barrett; Michael Doherty Journal: J Lipid Res Date: 2018-07-09 Impact factor: 5.922
Authors: Eiva Bernotiene; Edvardas Bagdonas; Gailute Kirdaite; Paulius Bernotas; Ursule Kalvaityte; Ilona Uzieliene; Christian S Thudium; Heidi Hannula; Gabriela S Lorite; Mona Dvir-Ginzberg; Ali Guermazi; Ali Mobasheri Journal: Front Med (Lausanne) Date: 2020-10-21
Authors: Mukundan Attur; Svetlana Krasnokutsky; Hua Zhou; Jonathan Samuels; Gregory Chang; Jenny Bencardino; Pamela Rosenthal; Leon Rybak; Janet L Huebner; Virginia B Kraus; Steven B Abramson Journal: Arthritis Res Ther Date: 2020-09-10 Impact factor: 5.156